本帖最后由 老马 于 2013-3-13 13:43 编辑
* n1 O. O, |6 H9 |6 C
4 n) p, |% x% y! r% {9 Q: ]健择(吉西他滨)+顺铂+阿瓦斯汀! P+ ?5 Z" _& v9 }0 r/ d: G
Gemzar +Cisplatin + Avastin- R- @& N2 ?! V u- ?, y5 b
http://annonc.oxfordjournals.org/content/21/9/1804.full+ }* g7 N; g- F8 a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 J: [2 q& ]1 t$ y6 z& g% o9 pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) E2 i7 [/ ^; ^0 U+ e3 a: ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ) [1 i8 o4 b) S; ~. G* V$ j) {
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 759)
5 e+ ?; E; v; ~
华为网盘附件:+ @' {6 Y7 a2 T, v6 v$ b( ^+ `
【华为网盘】ava.JPG
" {. {0 J( Q5 ^- g0 L4 v |